Hansoh Pharmaceutical Group Company Limited

SEHK:3692 주식 보고서

시가총액: HK$108.4b

Hansoh Pharmaceutical Group 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Huijuan Zhong

최고 경영자

CN¥14.8m

총 보상

CEO 급여 비율49.6%
CEO 임기8.9yrs
CEO 소유권n/a
경영진 평균 재임 기간8.7yrs
이사회 평균 재임 기간7.1yrs

최근 관리 업데이트

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Nov 21
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Rather Sparingly

Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Nov 04
Is Now The Time To Put Hansoh Pharmaceutical Group (HKG:3692) On Your Watchlist?

Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Aug 28
Estimating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

Aug 07
Pinning Down Hansoh Pharmaceutical Group Company Limited's (HKG:3692) P/E Is Difficult Right Now

If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Jul 16
If EPS Growth Is Important To You, Hansoh Pharmaceutical Group (HKG:3692) Presents An Opportunity

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Jun 24
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 06
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) CEO Will Probably Find It Hard To See A Huge Raise This Year

Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

May 23
Estimating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 01
Hansoh Pharmaceutical Group Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

Mar 28
Do Hansoh Pharmaceutical Group's (HKG:3692) Earnings Warrant Your Attention?

There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

Mar 04
There's Reason For Concern Over Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Massive 28% Price Jump

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Feb 16
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 28% Undervalued

Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Dec 08
Hansoh Pharmaceutical Group (HKG:3692) Seems To Use Debt Quite Sensibly

Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Oct 12
Hansoh Pharmaceutical Group Company Limited (HKG:3692) Shares Could Be 25% Below Their Intrinsic Value Estimate

Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

Sep 14
Hansoh Pharmaceutical Group's (HKG:3692) Upcoming Dividend Will Be Larger Than Last Year's

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Sep 09
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jul 10
Calculating The Intrinsic Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Jun 11
These 4 Measures Indicate That Hansoh Pharmaceutical Group (HKG:3692) Is Using Debt Reasonably Well

Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Jan 23
Calculating The Fair Value Of Hansoh Pharmaceutical Group Company Limited (HKG:3692)

Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Dec 01
Hansoh Pharmaceutical Group (HKG:3692) Has A Rock Solid Balance Sheet

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Oct 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Intrinsic Value Is Potentially 65% Above Its Share Price

Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

Aug 28
Hansoh Pharmaceutical Group (HKG:3692) Could Easily Take On More Debt

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Jun 09
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 44% Undervalued

Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

May 19
Hansoh Pharmaceutical Group Company Limited's (HKG:3692) Popularity With Investors Is Under Threat From Overpricing

Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

Apr 22
Is Hansoh Pharmaceutical Group (HKG:3692) A Risky Investment?

An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

Feb 06
An Intrinsic Calculation For Hansoh Pharmaceutical Group Company Limited (HKG:3692) Suggests It's 45% Undervalued

CEO 보상 분석

Huijuan Zhong 의 보수는 Hansoh Pharmaceutical Group 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

CN¥5b

Mar 31 2024n/an/a

CN¥4b

Dec 31 2023CN¥15mCN¥7m

CN¥3b

Sep 30 2023n/an/a

CN¥3b

Jun 30 2023n/an/a

CN¥3b

Mar 31 2023n/an/a

CN¥3b

Dec 31 2022CN¥11mCN¥5m

CN¥3b

Sep 30 2022n/an/a

CN¥3b

Jun 30 2022n/an/a

CN¥3b

Mar 31 2022n/an/a

CN¥3b

Dec 31 2021CN¥16mCN¥8m

CN¥3b

보상 대 시장: Huijuan 의 총 보상 ($USD 2.04M )은 Hong Kong 시장( $USD 906.49K ).

보상과 수익: Huijuan 의 보상은 지난 1년 동안 20% 이상 증가했습니다.


CEO

Huijuan Zhong (63 yo)

8.9yrs

테뉴어

CN¥14,807,000

보상

Ms. Huijuan Zhong is the Chairlady, Chief Executive Officer, President and Executive Director of Hansoh Pharmaceutical Group Company Limited since December 2, 2015. Ms. Zhong was appointed as a Director of...


리더십 팀

이름위치테뉴어보상소유권
Huijuan Zhong
Chairlady8.9yrsCN¥14.81m데이터 없음
Aifeng Lyu
Executive Director8.7yrsCN¥9.39m0.023%
HK$ 25.3m
Yuan Sun
Executive Director8.9yrsCN¥16.63m0.021%
HK$ 22.8m
Min Hu
VP & CFOno data데이터 없음데이터 없음
Chih-Hung Lee
Chief of Science Officer2.6yrs데이터 없음데이터 없음
Chuanhe Xu
Senior Vice President15.7yrs데이터 없음데이터 없음
Weiyong Sun
Chief Commercial Officerno data데이터 없음데이터 없음
Shengli Zhong
Joint Company Secretary & Senior VP6.3yrs데이터 없음데이터 없음
Sze Wai Tam
Joint Company Secretaryless than a year데이터 없음데이터 없음

8.7yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 3692 의 관리팀은 노련하고 경험 (평균 재직 기간 8.7 년)입니다.


이사회 구성원

이름위치테뉴어보상소유권
Huijuan Zhong
Chairlady8.9yrsCN¥14.81m데이터 없음
Aifeng Lyu
Executive Director8.7yrsCN¥9.39m0.023%
HK$ 25.3m
Yuan Sun
Executive Director8.9yrsCN¥16.63m0.021%
HK$ 22.8m
Guoqiang Lin
Independent Non-Executive Director5.5yrsCN¥360.00k데이터 없음
Sheung Wai Chan
Independent Non-Executive Director5.5yrsCN¥360.00k데이터 없음
Dongtao Yang
Independent Non-Executive Director5.5yrsCN¥360.00k데이터 없음

7.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: 3692 의 이사회경험(평균 재직 기간 7.1 년)으로 간주됩니다.